Skip to main content

Current status of Taxotere® (docetaxel) as a new treatment in breast cancer

Summary

Therapy for advanced breast cancer has not improved significantly in recent years, remaining strictly palliative in nature and intent. One approach to increase the effectiveness of the treatment is the introduction of active new drugs. Taxotere® (docetaxel) is a taxoid derivative isolated from the needles of the European yew,Taxus baccata. Taxotere promotes the assembly of microtubules and inhibits their depolymerization. One EORTC Clinical Screening Group (CSG) phase II trial using Taxotere at 100 mg/m2, 1 hour infusion without routine premedication for hypersensitivity reactions, in first line chemotherapy, indicates a high anti-tumor activity: 5 complete and 18 partial responses in 32 patients assessable for response (overall response rate 72%, 95% CI 53%–86%). Other studies confirm this activity in first line and second line chemotherapy for advanced disease and in patients who are refractory to anthracycline containing regimens. Grades III and IV neutropenia without major infection, and grades I and II skin toxicity, were frequently observed adverse events. A fluid retention syndrome (chronic cumulative and non life-threatening toxicity) has been noted in patients treated with Taxotere. Methods for controlling fluid retention — dose reduction to 75 mg/m2 (which has little effect) or routine premedication from the start of treatment — are currently being studied.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Peto R: Treatment of Early Breast Cancer, Early Breast Cancer Trialists' Collaborative Group, vol. I. Oxford, UK, Oxford Medical Publication, 1991

    Google Scholar 

  2. 2.

    Henderson IC: Chemotherapy of breast cancer. Cancer 51:2553–2559, 1983

    Google Scholar 

  3. 3.

    Osborne CK: Breast cancer.In: Wittes RE (ed) Manual of Oncologic Therapeutics 1989/1990. Lippincott, Philadelphia, 1989, pp 201–211

    Google Scholar 

  4. 4.

    Williams SF, Mich R, et al: High dose consolidation therapy with autologous stem cell rescue in Stage IV breast cancer. J Clin Oncol 7:1824–1830, 1989

    Google Scholar 

  5. 5.

    Henderson IC: Chemotherapy of advanced disease.In: Harris JR, Henderson IC, Hellman S, Kinne DN (eds) Breast Diseases. Lippincott, Philadelphia, 1987, pp 428–479

    Google Scholar 

  6. 6.

    Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analog. Cancer Res 51:4845–4852, 1991

    Google Scholar 

  7. 7.

    Ringel I, Horwitz SB: Studies with RP56976 (Taxotere): a semi synthetic analogue of taxol. J Natl Cancer Inst 83:288–291, 1991

    Google Scholar 

  8. 8.

    Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M: Phase I and pharmacokinetic study of Taxotere (RP56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037–1042, 1993

    Google Scholar 

  9. 9.

    Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB, Kerr DJ: Phase I and pharmacokinetic study of Taxotere (RP56976) administered as a 24-hour infusion. Cancer Res 53:523–527, 1993

    Google Scholar 

  10. 10.

    Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B, Moore D Jr, Jaiyesimi I, Vreeland F, Bayssas M, M G, Raber MN: Phase I trial of Taxotere: five day schedule. J Natl Cancer Inst 84:1781–1788, 1992

    Google Scholar 

  11. 11.

    Burris HA, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, Fields S, Weiss G, Eckardt J, Rodriguez G, Rinaldi D, Wall J, Vreeland F, Bayssas M, Le Bail N, Von Hoff D: Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour infusion. J Clin Oncol 11:950–958, 1993

    Google Scholar 

  12. 12.

    De Valeriola D, Brassinne C, Piccart M, Tomiak E, Kerger J, Awada A, Ravoel C, Lips S, Auzannet V, Le Bail N, Bruno R, Klastersky J: Phase I pharmacokinetic study of Taxotere (RP56976) administered as a weekly infusion. Proc AACR 33:1563, 1992

    Google Scholar 

  13. 13.

    Fumoleau P, Chevallier B, Kerbrat P, Dieras V, Le Bail N, Bayssas M, Van Glabbeke M: First line chemotherapy with Taxotere in advanced breast cancer: a phase II study of the EORTC Clinical Screening Group. Proc ASCO 12:56, 1993

    Google Scholar 

  14. 14.

    Trudeau ME, Eisenhauer E, Lofters W, Norris B, Muldal A, Letendre F, Vandenburg T, Verma S: Phase II study of Taxotere as first line chemotherapy for metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Proc ASCO 12:64, 1993

    Google Scholar 

  15. 15.

    Seidman AD, Hudis C, Crown JPA, Balmaceda C, Lebwohl D, Currie V, Gilewski T, Hakes T, Robles M, Klem K, Lepore J, Norton L: Phase II evaluation of Taxotere (RP56976, NSC 628503) as initial chemotherapy for metastatic breast cancer. Proc ASCO 12:63, 1993

    Google Scholar 

  16. 16.

    Ten Bokkel Huinink WW, Van Oosterom AT, Piccart M, Franklin H, Wanders J, Bayssas M, Kaye SB: Taxotere (docetaxel) in advanced breast cancer; a phase II trial of the EORTC Early Clinical Trials Group. Proc ASCO 12:70, 1993 (abstract 81)

    Google Scholar 

  17. 17.

    Valero V, Esparza L, Theriault RL, Walters R, Holmes FA, Fraschini G, Dhingra K, Buzdar AU, Bellet R, Slattery A, Pazdur R, Raber MN, Bayssas M, Hortobagyi GN: Phase II study of Taxotere (docetaxel) in refractory metastatic breast cancer. 18th Int Congr Chemotherapy, June 27-July 2, 1993, Stockholm

  18. 18.

    Wanders J, Schrijvers D, Bruntsch U, Gore M, Verweij J, Hanauske AR, Franklin H, Roelvink M, Bayssas M, Kaye SB: The EORTC-ECTG experience with acute hypersensitivity reactions in Taxotere (docetaxel) studies. Proc ASCO 12:73, 1993

    Google Scholar 

  19. 19.

    New P: Neurotoxicity of Taxotere (docetaxel). Proc AACR 34:233, 1993

    Google Scholar 

  20. 20.

    Harris JR, Hellman S, Henderson C, et al: Breast Diseases. Lippincott, Philadelphia PA, 1991

    Google Scholar 

  21. 21.

    Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, Goudier MJ, Chollet P, Lecourt L, Montcuquet P: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245–1252, 1993

    Google Scholar 

  22. 22.

    Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in metastatic breast cancer. J Natl Cancer Inst 83:1797–1805, 1991

    Google Scholar 

  23. 23.

    Seidman A, Reichman B, Crown J, et al: Activity of Taxol with recombinant granulocyte colony stimulating factor (G-CSF) as first chemotherapy of patients with metastatic breast cancer. Proc ASCO 11:59, 1992

    Google Scholar 

  24. 24.

    Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, Van Oosterom A, Kaye S: Coping with toxicities of docetaxel (TaxotereTM). Ann Oncol 4:610–611, 1993

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to P. Fumoleau.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fumoleau, P., Chevallier, B., Kerbrat, P. et al. Current status of Taxotere® (docetaxel) as a new treatment in breast cancer. Breast Cancer Res Tr 33, 39–46 (1995). https://doi.org/10.1007/BF00666069

Download citation

Key words

  • breast cancer
  • phase II trials
  • Taxotere® (docetaxel)
  • taxoids